At present, discovering the right enzymes for production in drug development can prove both prohibitively expensive and time consuming, as identifying the right enzyme is a trial and error process that can see companies go through potentially thousands of enzymes during the search. This prevents the penetration of enzymes in the industries like pharma where effective and green technologies are crucial.
EnzBond launches to make fast, effective enzyme development a reality
13 December 2016
EnzBond, a new biotechnology company from Oxford University, has been formed to commercialise in-silico technology, which makes utilising enzymes in drug manufacturing both cost-effective and time-efficient.